There are so many important dimensions to this product that are highly valued by the investment community (and support a large market valuation). If approval happens, one of the things that we will see emerge quickly is a focus on the COST SAVINGS of this product vs. what is available in the market today. I can only imagine that the insurance providers, doctors, and hospitals are going to want to bring a less expensive treatment option front and center.
We will see top doctors (like the Dr. in Philly who went with AMIC to the FDA meeting) also extolling the virtues of this treatment publicly at conferences, and writing about it, etc. It could be very exciting for us shareholders!
News 
Market Data 
Discover 
